KRAS and cancer: BI-2865, a novel pan-KRAS inhibitor, demonstrates activity against a broad spectrum of KRAS mutations—including G12C/D/F/V, G13C/D, and V14I—potentially covering up to 95% of KRAS-driven cancers, thus holding substantial therapeutic promise.